Table 1.
Demographics and clinical findings of 11 patients with cytomegalovirus and anterior segment inflammation treated with oral valganciclovir
| Patient | Gender/age | Diagnosis | Prior surgery | Follow-up duration (months) | Duration of maintenance therapy (months) | Recurrence | Interval between recurrence and stopping valganciclovir therapy (months) | Baseline VA | Final VA | Lines changed | Baseline IOP (mmHg) | Final IOP (mmHg) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 (OD) | M/60 | Endotheliitis | PK, Trab | 38 | 36 | Yes | 4 | 20/70 | 20/800 | −12 | 21 | 14 |
| 1 (OS) | M/60 | Endotheliitis | PK, Trab | 38 | 36 | No | N/A | 20/800 | 20/70 | +12 | 8 | 9 |
| 2 (OD) | F/50 | Endotheliitis | None | 13 | 3.5 | No | N/A | 20/100 | 20/40 | +4 | 30 | 12 |
| 2 (OS) | F/50 | Endotheliitis | None | 13 | 3.5 | No | N/A | 20/30 | 20/20 | +2 | 12 | 16 |
| 3 | M/57 | Endotheliitis | Trab | 24 | 2 | No | N/A | 20/1600 | 20/20 | +18 | 16 | 17 |
| 4 | M/59 | FUS | None | 12 | 2 | Yes | 4 | 20/25 | 20/20 | +1 | 27 | 7 |
| 5 | F/50 | FUS | Trab | 6 | 2.5 | No | N/A | 20/25 | 20/25 | +1 | 8 | 8 |
| 6 | M/49 | FUS | None | 15 | 2.5 | No | N/A | 20/100 | 20/20 | +7 | 15 | 8 |
| 7 | M/48 | PSS | None | 6 | 3.5 | No | N/A | 20/70 | 20/25 | +4 | 21 | 17 |
| 8 | F/39 | PSS | None | 17 | 2.5 | Yes | 1 | 20/30 | 20/30 | +0 | 23 | 16 |
| 9 | M/58 | PSS | Phaco, Trab | 23 | 3.5 | No | N/A | 20/70 | 20/800 | −12 | 18 | 6 |
| 10 | M/28 | PSS | None | 6 | 7 | Yes | 2 | 20/20 | 20/18 | +1 | 11 | 11 |
| 11 | M/70 | PSS | Phaco | 29 | 27 | Yes | 1 | 20/70 | 20/25 | +4 | 28 | 11 |
Abbreviations: M, male; F, female; PSS, Posner-Schlossmann syndrome; FUS, Fuchs uveitis syndrome; PK, penetrating keratoplasty; Trab, trabeculectomy; Phaco, phacoemulsification; VA, visual acuity; IOP, intraocular pressure; N/A, not applicable.